提示: 手机请竖屏浏览!

Evidence for Health Decision Making — Beyond Randomized, Controlled Trials

Thomas R. Frieden ... 其他 • 2017.08.03



Thomas R. Frieden, M.D., M.P.H.
From Atlanta, GA. The author is the former director of the Centers for Disease Control and Prevention. Address reprint requests to Dr. Frieden at tfrieden@gmail.com.



1. Centers for Disease Control and Prevention. Mission, role and pledge (http://www.cdc.gov/about/organization/mission.htm).

2. Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet 2005;365:82-93

3. Jones DS, Podolsky SH. The history and fate of the gold standard. Lancet 2015;385:1502-1503

4. Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the gold standard — lessons from the history of RCTs. N Engl J Med 2016;374:2175-2181

5. Kones R, Rumana U, Merino J. Exclusion of ‘nonRCT evidence’ in guidelines for chronic diseases — is it always appropriate? The Look AHEAD study. Curr Med Res Opin 2014;30:2009-2019

6. Chavez-MacGregor M, Giordano SH. Randomized clinical trials and observational studies: is there a battle? J Clin Oncol 2016;34:772-773

7. Deaton A. Instruments, randomization, and learning about development. J Econ Lit 2010;48:424-455

8. Woodcock J, Ware JH, Miller PW, McMurray JJV, Harrington DP, Drazen JM. Clinical trial series. N Engl J Med 2016;374:2167-2167

9. Mitchell EA, Scragg R, Stewart AW, et al. Results from the first year of the New Zealand Cot Death Study. N Z Med J 1991;104:71-76

10. Irving M, Eramudugolla R, Cherbuin N, Anstey KJ. A critical review of grading systems: implications for public health policy. Eval Health Prof 2016 May 10 (Epub ahead of print)

11. Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials. Am J Med 1982;72:233-240

12. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006;35:337-344

13. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-1892

14. Golfam M, Beall R, Brehaut J, et al. Comparing alternative design options for chronic disease prevention interventions. Eur J Clin Invest 2015;45:87-99

15. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-461

16. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-333

17. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women’s Health Initiative clinical trial. Am J Epidemiol 2005;162:404-414

18. Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women’s Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006;163:589-599

19. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-1368

20. Vandenbroucke JP. The HRT controversy: observational studies and RCTs fall in line. Lancet 2009;373:1233-1235

21. Mendelsohn ME, Karas RH. HRT and the young at heart. N Engl J Med 2007;356:2639-2641

22. Nasal influenza vaccine approved for younger children. Food and Drug Administration Consumer Updates. September 26, 2007 (https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048715.htm).

23. Ashkenazi S, Vertruyen A, Arístegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006;25:870-879

24. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006;25:860-869

25. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685-696

26. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) — United States, 2014–15 influenza season. MMWR Morb Mortal Wkly Rep 2014;63:691-697

27. Gaglani M, Pruszynski J, Murthy K, et al. Influenza vaccine effectiveness against the 2009 Pandemic A (H1N1) virus differed by vaccine-type during 2013-14 in the United States. J Infect Dis 2016;213:1546-1556

28. Flannery B. Update on effectiveness of live-attenuated versus inactivated influenza vaccines in children and adolescents aged 2-18 years — US Flu VE Network. Presented at the Meeting of the Advisory Committee on Immunization Practices, Atlanta, October 29–30, 2014 (http://www.nitag-resource.org/uploads/media/default/0001/02/a4c56839e81370e3d8635468dddee24ac681d2da.pdf).

29. Chung JR, Flannery B, Thompson MG, et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics 2016;137:e20153279-e20153279

30. ACIP votes down use of LAIV for 2016-2017 flu season. Media statement from the Centers for Disease Control and Prevention, June 22, 2016 (http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html).

31. Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;2:769-782

32. Iseman MD, Sbarbaro JA. Short-course chemotherapy of tuberculosis: hail Britannia (and friends)! Am Rev Respir Dis 1991;143:697-698

33. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005;171:699-706

34. Fox W. Self-administration of medicaments: a review of published work and a study of the problems. Bull Int Union Tuberc 1962;32:307-331

35. Dawson JJY, Devadatta S, Fox W, et al. A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS. Bull World Health Organ 1966;34:533-551

36. Treatment of tuberculosis: guidelines for national programmes. Geneva: World Health Organization, 1997.

37. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998;352:1340-1343

38. Akkslip S, Rasmithat S, Maher D, Sawert H. Direct observation of tuberculosis treatment by supervised family members in Yasothorn Province, Thailand. Int J Tuberc Lung Dis 1999;3:1061-1065

39. Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 2003;326:574-574

40. Moonan PK, Quitugua TN, Pogoda JM, et al. Does directly observed therapy (DOT) reduce drug resistant tuberculosis? BMC Public Health 2011;11:19-19

41. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996;276:1229-1235

42. Xu JQ, Murphy SL, Kochanek KD, Bastian BA. Deaths: final data for 2013. Natl Vital Stat Rep 2016;64():1-119.

43. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief 2013;133:1-8

44. Institute of Medicine. Strategies to reduce sodium intake in the United States. Washington, DC: National Academies Press, 2010.

45. Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014;371:624-634

46. He FJ, Pombo-Rodrigues S, Macgregor GA. Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality. BMJ Open 2014;4:e004549-e004549

47. He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet 2011;378:380-382

48. Cook NR, Appel LJ, Whelton PK. Sodium intake and all-cause mortality over 20 years in the trials of hypertension prevention. J Am Coll Cardiol 2016;68:1609-1617

49. Mente A, O’Donnell M, Rangarajan S, et al. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet 2016;388:465-475

50. Graudal N, Jürgens G, Baslund B, Alderman MH. Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. Am J Hypertens 2014;27:1129-1137

51. O’Donnell M, Mente A, Rangarajan S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med 2014;371:612-623

52. Cobb LK, Anderson CA, Elliott P, et al. Methodological issues in cohort studies that relate sodium intake to cardiovascular disease outcomes: a science advisory from the American Heart Association. Circulation 2014;129:1173-1186

53. Willett W. Nutritional epidemiology: monographs in epidemiology and biostatistics. 3rd ed. New York: Oxford University Press, 2013.

54. He FJ, MacGregor GA. Hypertension: salt: flawed research should not divert actions to reduce intake. Nat Rev Nephrol 2016;12:514-515

55. Cogswell ME, Maalouf J, Elliott P, Loria CM, Patel S, Bowman BA. Use of urine biomarkers to assess sodium intake: challenges and opportunities. Annu Rev Nutr 2015;35:349-387

56. Rakova N, Jüttner K, Dahlmann A, et al. Long-term space flight simulation reveals infradian rhythmicity in human Na(+) balance. Cell Metab 2013;17:125-131

57. Cogswell ME, Mugavero K, Bowman BA, Frieden TR. Dietary sodium and cardiovascular disease risk — measurement matters. N Engl J Med 2016;375:580-586

58. Multiple Risk Factor Intervention Trial Group. The Multiple Risk Factor Intervention Trial (MRFIT): a national study of primary prevention of coronary heart disease. JAMA 1976;235:825-827

59. Frieden TR. Sodium reduction — saving lives by putting choice into consumers’ hands. JAMA 2016;316:579-580

60. Schieppati A, Henter J-I, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008;371:2039-2041

61. Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009;96:20-26

62. Rubinstein YR, Groft SC, Bartek R, et al. Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). Contemp Clin Trials 2010;31:394-404

63. Frakt AB. An observational study goes where randomized clinical trials have not. JAMA 2015;313:1091-1092

64. Lederle FA, Cushman WC, Ferguson RE, Brophy MT, Fiore Md LD. Chlorthalidone versus hydrochlorothiazide: a new kind of Veterans Affairs cooperative study. Ann Intern Med 2016;165:663-664

65. Ernst ME, Lund BC. Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. J Clin Hypertens (Greenwich) 2010;12:927-934

66. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012;59:1110-1117

67. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997

68. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011;57:689-694

69. Woolever DR. The art and science of clinical decision making. Fam Pract Manag 2008;15:31-36

70. Groopman J. How doctors think. Boston: Houghton Mifflin, 2007.

71. Angus DC. Fusing randomized trials with big data: the key to self-learning health care systems? JAMA 2015;314:767-768

72. Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 2007;43:859-866

73. Moss AJ, Francis CW, Ryan D. Collaborative clinical trials. N Engl J Med 2011;364:789-791

74. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65-74

75. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22

76. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158

77. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696

78. Khan M, Qureshi AI. Factors associated with increased rates of post-procedural stroke or death following carotid artery stent placement: a systematic review. J Vasc Interv Neurol 2014;7:11-20

79. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278

80. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681

81. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis — effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-1471

82. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659-669

83. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010;304:2373-2380

84. Tai V, Grey A, Bolland MJ. Results of observational studies: analysis of findings from the Nurses’ Health Study. PLoS One 2014;9:e110403-e110403

85. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-1695

86. Zou B, Li T, Zhou Q, et al. Adjuvant therapeutic modalities in primary small cell carcinoma of esophagus patients: a retrospective cohort study of multicenter clinical outcomes. Medicine (Baltimore) 2016;95:e3507-e3507

87. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606-b4606

88. Gottlieb SL, Newbern EC, Griffin PM, et al. Multistate outbreak of listeriosis linked to turkey deli meat and subsequent changes in US regulatory policy. Clin Infect Dis 2006;42:29-36

89. D’Souza G, Kreimer AR, Viscidi R, et al. Case–control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956

90. Cohen AT, Tapson VF, Bergmann J-F, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371:387-394

91. Mastrangelo G, Fedeli U, Visentin C, Milan G, Fadda E, Spolaore P. Pattern and determinants of hospitalization during heat waves: an ecologic study. BMC Public Health 2007;7:200-200

92. Fairall L, Bachmann MO, Lombard C, et al. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet 2012;380:889-898

93. Wisotzky M, Albuquerque M, Pechacek TF, Park BZ. The National Tobacco Control Program: focusing on policy to broaden impact. Public Health Rep 2004;119:303-310

94. Pneumocystis pneumonia — Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-252

95. Schuler-Faccini L, Ribeiro EM, Feitosa IM, et al. Possible association between Zika virus infection and microcephaly — Brazil, 2015. MMWR Morb Mortal Wkly Rep 2016;65:59-62

96. Fleming A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 1929;10:226-236

97. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease: a collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J 2012;163:399-406

98. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-172

服务条款 | 隐私政策 | 联系我们